Home > Research > Publications & Outputs > Utilising high-dimensional data in randomised c...

Associated organisational unit

Electronic data

  • 2305.10174

    Accepted author manuscript, 765 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

View graph of relations

Utilising high-dimensional data in randomised clinical trials: a review of methods and practice

Research output: Contribution to Journal/MagazineJournal articlepeer-review

E-pub ahead of print

Standard

Utilising high-dimensional data in randomised clinical trials: a review of methods and practice. / Cherlin, Svetlana; Bigirumurame, Theophile; Grayling, Michael et al.
In: Research Methods in Medicine & Health Sciences, 25.12.2023.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Cherlin, S, Bigirumurame, T, Grayling, M, Nsengimana, J, Ouma, L, Santaolalla, A, Wan, F, Williamson, F & Wason, J 2023, 'Utilising high-dimensional data in randomised clinical trials: a review of methods and practice', Research Methods in Medicine & Health Sciences. https://doi.org/10.1177/26320843231186399

APA

Cherlin, S., Bigirumurame, T., Grayling, M., Nsengimana, J., Ouma, L., Santaolalla, A., Wan, F., Williamson, F., & Wason, J. (2023). Utilising high-dimensional data in randomised clinical trials: a review of methods and practice. Research Methods in Medicine & Health Sciences. Advance online publication. https://doi.org/10.1177/26320843231186399

Vancouver

Cherlin S, Bigirumurame T, Grayling M, Nsengimana J, Ouma L, Santaolalla A et al. Utilising high-dimensional data in randomised clinical trials: a review of methods and practice. Research Methods in Medicine & Health Sciences. 2023 Dec 25. Epub 2023 Dec 25. doi: 10.1177/26320843231186399

Author

Cherlin, Svetlana ; Bigirumurame, Theophile ; Grayling, Michael et al. / Utilising high-dimensional data in randomised clinical trials : a review of methods and practice. In: Research Methods in Medicine & Health Sciences. 2023.

Bibtex

@article{180dc9bf8fca4ea2a7bfc5c06ec7251a,
title = "Utilising high-dimensional data in randomised clinical trials: a review of methods and practice",
abstract = "IntroductionEven in effectively conducted randomised trials, the probability of a successful study remains relatively low. With recent advances in the next-generation sequencing technologies, there is a rapidly growing number of high-dimensional data, including genetic, molecular and phenotypic information, that have improved our understanding of driver genes, drug targets, and drug mechanisms of action. The leveraging of high-dimensional data holds promise for increased success of clinical trials.MethodsWe provide an overview of methods for utilising high-dimensional data in clinical trials. We also investigate the use of these methods in practice through a review of recently published randomised clinical trials that utilise high-dimensional genetic data. The review includes articles that were published between 2019 and 2021, identified through the PubMed database.ResultsOut of 174 screened articles, 100 (57.5%) were randomised clinical trials that collected high-dimensional data. The most common clinical area was oncology (30%), followed by chronic diseases (28%), nutrition and ageing (18%) and cardiovascular diseases (7%). The most common types of data analysed were gene expression data (70%), followed by DNA data (21%). The most common method of analysis (36.3%) was univariable analysis. Articles that described multivariable analyses used standard statistical methods. Most of the clinical trials had two arms.DiscussionNew methodological approaches are required for more efficient analysis of the increasing amount of high-dimensional data collected in randomised clinical trials. We highlight the limitations and barriers to the current use of high-dimensional data in trials, and suggest potential avenues for improvement and future work.",
author = "Svetlana Cherlin and Theophile Bigirumurame and Michael Grayling and Jeremie Nsengimana and Luke Ouma and Aida Santaolalla and Fang Wan and Faye Williamson and James Wason",
year = "2023",
month = dec,
day = "25",
doi = "10.1177/26320843231186399",
language = "English",
journal = "Research Methods in Medicine & Health Sciences",

}

RIS

TY - JOUR

T1 - Utilising high-dimensional data in randomised clinical trials

T2 - a review of methods and practice

AU - Cherlin, Svetlana

AU - Bigirumurame, Theophile

AU - Grayling, Michael

AU - Nsengimana, Jeremie

AU - Ouma, Luke

AU - Santaolalla, Aida

AU - Wan, Fang

AU - Williamson, Faye

AU - Wason, James

PY - 2023/12/25

Y1 - 2023/12/25

N2 - IntroductionEven in effectively conducted randomised trials, the probability of a successful study remains relatively low. With recent advances in the next-generation sequencing technologies, there is a rapidly growing number of high-dimensional data, including genetic, molecular and phenotypic information, that have improved our understanding of driver genes, drug targets, and drug mechanisms of action. The leveraging of high-dimensional data holds promise for increased success of clinical trials.MethodsWe provide an overview of methods for utilising high-dimensional data in clinical trials. We also investigate the use of these methods in practice through a review of recently published randomised clinical trials that utilise high-dimensional genetic data. The review includes articles that were published between 2019 and 2021, identified through the PubMed database.ResultsOut of 174 screened articles, 100 (57.5%) were randomised clinical trials that collected high-dimensional data. The most common clinical area was oncology (30%), followed by chronic diseases (28%), nutrition and ageing (18%) and cardiovascular diseases (7%). The most common types of data analysed were gene expression data (70%), followed by DNA data (21%). The most common method of analysis (36.3%) was univariable analysis. Articles that described multivariable analyses used standard statistical methods. Most of the clinical trials had two arms.DiscussionNew methodological approaches are required for more efficient analysis of the increasing amount of high-dimensional data collected in randomised clinical trials. We highlight the limitations and barriers to the current use of high-dimensional data in trials, and suggest potential avenues for improvement and future work.

AB - IntroductionEven in effectively conducted randomised trials, the probability of a successful study remains relatively low. With recent advances in the next-generation sequencing technologies, there is a rapidly growing number of high-dimensional data, including genetic, molecular and phenotypic information, that have improved our understanding of driver genes, drug targets, and drug mechanisms of action. The leveraging of high-dimensional data holds promise for increased success of clinical trials.MethodsWe provide an overview of methods for utilising high-dimensional data in clinical trials. We also investigate the use of these methods in practice through a review of recently published randomised clinical trials that utilise high-dimensional genetic data. The review includes articles that were published between 2019 and 2021, identified through the PubMed database.ResultsOut of 174 screened articles, 100 (57.5%) were randomised clinical trials that collected high-dimensional data. The most common clinical area was oncology (30%), followed by chronic diseases (28%), nutrition and ageing (18%) and cardiovascular diseases (7%). The most common types of data analysed were gene expression data (70%), followed by DNA data (21%). The most common method of analysis (36.3%) was univariable analysis. Articles that described multivariable analyses used standard statistical methods. Most of the clinical trials had two arms.DiscussionNew methodological approaches are required for more efficient analysis of the increasing amount of high-dimensional data collected in randomised clinical trials. We highlight the limitations and barriers to the current use of high-dimensional data in trials, and suggest potential avenues for improvement and future work.

U2 - 10.1177/26320843231186399

DO - 10.1177/26320843231186399

M3 - Journal article

JO - Research Methods in Medicine & Health Sciences

JF - Research Methods in Medicine & Health Sciences

ER -